Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JAB-BX600
- Development stage
- Preclinical
- Lead developer
- Jacobio Pharmaceuticals Co., Ltd.
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
JAB-BX600 is a first-in-class targeted antibody-drug conjugate (tADC) developed by Jacobio Pharma (Beijing Jiakesi New Drug Development). It is designed to treat cancers harboring KRAS G12D mutations by utilizing an EGFR-targeting monoclonal antibody as a carrier to deliver a potent small-molecule KRAS G12D inhibitor payload, JAB-22000, directly to tumor cells. This dual-action approach exploits the synergistic effects of EGFR inhibition and KRAS G12D inhibition, potentially overcoming resistance mechanisms associated with single-agent therapies. JAB-BX600 is currently in the IND-enabling stage, with primary development focuses on pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), and non-small cell lung cancer (NSCLC).
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)
Beyond the preview
Go deeper on JAB-BX600.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JAB-BX600.